Drug Trial Radar · NCT06960213
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Aug 28, 2025
Primary completion
Nov 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- ADARx Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.
Conditions
- Hereditary Angioedema
- HAE
- Hereditary Angioedema - Type 1
- Hereditary Angioedema - Type 2
Interventions
ADX-324Drug
siRNA duplex oligonucleotide
PlaceboDrug
saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of ADX-324 in preventing HAE attacksTime frame: Day 22 to Week 25
Locations
70 sites in 24 countries. Site status is shown where the registry gives one.
ADARx Clinical Site
Litchfield Park, Arizona · Recruiting
ADARx Clinical Site
Scottsdale, Arizona · Recruiting
ADARx Clinical Site
Little Rock, Arkansas · Recruiting
ADARx Clinical Site
San Diego, California · Recruiting
ADARx Clinical Site
Santa Monica, California · Not yet recruiting
ADARx Clinical Site
Walnut Creek, California · Recruiting
ADARx Clinical Site
Centennial, Colorado · Recruiting
ADARx Clinical Site
Orlando, Florida · Recruiting
ADARx Clinical Site
Chevy Chase, Maryland · Recruiting
ADARx Clinical Site
Wheaton, Maryland · Withdrawn
ADARx Clinical Site
Detroit, Michigan · Recruiting
ADARx Clinical Site
St Louis, Missouri · Recruiting
ADARx Clinical Site
Las Vegas, Nevada · Recruiting
ADARx Clinical Site
New York, New York · Recruiting
ADARx Clinical Site
Cincinnati, Ohio · Recruiting
ADARx Clinical Site
Cleveland, Ohio · Not yet recruiting
ADARx Clinical Site
Columbus, Ohio · Withdrawn
ADARx Clinical Site
Toledo, Ohio · Recruiting
ADARx Clinical Site
Hershey, Pennsylvania · Recruiting
ADARx Clinical Site
Pilar, Argentina · Recruiting
ADARx Clinical Site
Rosario, Argentina · Recruiting
ADARx Clinical Site
Capital Federal, Buenos Aires, Argentina · Recruiting
ADARx Clinical Site
Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
ADARx Clinical Site
Campbelltown, New South Wales, Australia · Not yet recruiting
ADARx Clinical Site
Adelaide, South Australia, Australia · Recruiting
ADARx Clinical Site
Vienna, Austria · Recruiting
ADARx Clinical Site
Edegem, Antwerpen, Belgium · Recruiting
ADARx Clinical Site
Campinas, Brazil · Not yet recruiting
ADARx Clinical Site
São Paulo, Brazil · Not yet recruiting
ADARx Clinical Site
Sofia, Bulgaria · Recruiting
ADARx Clinical Site
Edmonton, Alberta, Canada · Withdrawn
ADARx Clinical Site
Edmonton, Alberta, Canada · Not yet recruiting
ADARx Clinical Site
Ottawa, Ontario, Canada · Withdrawn
ADARx Clinical Site
Montreal, Quebec, Canada · Recruiting
ADARx Clinical Site
Beijing, China · Recruiting
ADARx Clinical Site
Harbin, China · Not yet recruiting
ADARx Clinical Site
Zhengzhou, China · Not yet recruiting
ADARx Clinical Site
Split, Croatia · Recruiting
ADARx Clinical Site
Zagreb, Croatia · Recruiting
ADARx Clinical Site
Hradec Králové, Czechia · Recruiting
Showing 40 of 70 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.